Trial Profile
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Jul 2012
Price :
$35
*
At a glance
- Drugs Bezisterim (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Harbor Therapeutics
- 07 Oct 2009 New trial record.